Inhaled Iloprost

PreclinicalSmall molecule

Bayer

Inhaled Iloprost is one of 2 small molecule programs targeting One-lung Ventilation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

One-Lung VentilationCompleted

One-Lung VentilationPreclinical

Completed

Competition

Competitive Landscape

1 competitor in One-Lung Ventilation

#DrugCompanyPhaseTrials

Iloprost Inhalation

Johnson & Johnson

Preclinical

1 2

Inhaled Iloprost

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation

Completed·YYonsei University·N/A·NCT02490657·44 enrolled

Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)

Unknown status·—·Phase 4·NCT01116063·15 enrolled

Pulmonary Hypertension2 trials

Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide

Terminated·—·Phase 4·NCT02170519·27 enrolled

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Terminated·UUniversity of Chicago·Phase 4·NCT00409526·1 enrolled

Efficacy1 trial

Efficacy of Ventavis Used in Real-life Setting.

Completed· Bayer logo

Bayer··NCT01355380·55 enrolled

Oxidative Stress1 trial

Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

Completed·LLouisiana State University Health Sciences Center in New Orleans·Phase 2·NCT01941225·24 enrolled

Pulmonary Arterial Hypertension1 trial

The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00302211·67 enrolled

3 more indications

Heart Transplantation1 trial

Iloprost for Bridging to Heart Transplantation in PH

Withdrawn·HHeidelberg University·Phase 2·NCT02482402

Respiratory Failure1 trial

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

Completed·HHamad Medical Corporation·Phase 2·NCT04445246·40 enrolled

One-lung Ventilation1 trial

The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery

Completed·SSeoul St. Mary's Hospital·N/A·NCT03936140·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Inhaled Iloprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled Iloprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled Iloprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Inhaled Iloprost

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Pulmonary Hypertension2 trials

Efficacy1 trial

Oxidative Stress1 trial

Pulmonary Arterial Hypertension1 trial

Heart Transplantation1 trial

Respiratory Failure1 trial

One-lung Ventilation1 trial

References

Drug Info

Quick Facts

Related News